Skip to main content

Table 2 Pathology of PDO-based xenografted liver metastases (PDOX-LM) models

From: A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases

Patient no. Mean CEA, ng/ml No. of grafts in spleen/total no. of grafts (%) No. of grafts in murine liver/total no. of grafts (%) No. of xenografted liver metastases, median (range)
3-week 5-week 7-week
mCRC
 1# 66.4 1834.8 12066.8 4/4 (100) 3/4 (75) 2 (2, 2)
 2# 93.2 202.4 424.6 3/4 (75) 3/4 (75) 2 (2, 4)
 3# 36.0 326.0 422.0 3/4 (75) 3/4 (75) 2 (2, 3)
 4# 277.8 1226.4 1775.4 4/4 (100) 3/4 (75) 3 (2, 4)
 5# 42.2 106.0 322.2 4/4 (100) 2/4 (50) 3.5 (2, 5)
 6# 11.4 44.2 306.6 4/4 (100) 1/4 (25) 4 (4, 4)
CRC
 7# 6.4 76.0 89.4 4/4 (100) 0/4 (0) /
 8# 11.2 16.6 13.2 3/4 (75) 0/4 (0) /
 9# 25.6 126.8 424.4 3/4 (75) 0/4 (0) /
 10# 2.2 2.8 11.8 2/4 (50) 0/4 (0) /
 11# 1.2 36.6 36.2 4/4 (100) 0/4 (0) /
 12# 1.8 2.2 4.2 2/4 (50) 0/4 (0) /